bioRxiv preprint doi: https://doi.org/10.1101/2020.07.15.199851; this version posted July 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Multi-sample Full-length Transcriptome Analysis of 22 Breast Cancer Clinical Specimens with Long-Read Sequencing Shinichi Namba1, §, Toshihide Ueno1, Shinya Kojima1, Yosuke Tanaka1, Satoshi Inoue1, Fumishi Kishigami1, Noriko Maeda2, Tomoko Ogawa3, Shoichi Hazama4, Yuichi Shiraishi5, Hiroyuki Mano1, and Masahito Kawazu1* Author affiliations: 1Division of Cellular Signaling, 5Division of Genome Analysis Platform Development, Research Institute, National Cancer Center, Tokyo 104-0045, Japan; 2Department of Gastroenterological, Breast and Endocrine Surgery, 4Department of Translational Research and Developmental Therapeutics against Cancer, Yamaguchi University Graduate School of Medicine, Yamaguchi 755-8505, Japan; 3Department of Breast Surgery, Mie University Hospital, Mie 514-8507, Japan; § Present address, Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; * Corresponding author E-mail:
[email protected] (MK) bioRxiv preprint doi: https://doi.org/10.1101/2020.07.15.199851; this version posted July 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Abstract Although transcriptome alteration is considered as one of the essential drivers of carcinogenesis, conventional short-read RNAseq technology has limited researchers from directly exploring full-length transcripts, only focusing on individual splice sites.